Uridine Improves Locomotor Activity and Sciatic Nerve Integrity in a Mouse Model of Diabetes Mellitus
Authors:
- Anca-Maria ȚucăAȚAnca-Maria Țucă
- Smaranda Ioana MitranSMSmaranda Ioana Mitran
- Emilia BuradaEBEmilia Burada
- Alexandra Nicoleta PredaAPAlexandra Nicoleta Preda
- Alexandra Oltea DanADAlexandra Oltea Dan
- Elena-Anca TârteaETElena-Anca Târtea
- Andrei GreșIțăAndrei GreșIță
- Răzvan-Cosmin PanăRPRăzvan-Cosmin Pană
- Diana-Ruxandra HădăreanuDHDiana-Ruxandra Hădăreanu
- Veronica SfredelVSVeronica Sfredel
- Georgică TârteaGTGeorgică Târtea
Open Access
- 20 May 2026
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 16 (5) , 750
Abstract
Diabetic peripheral neuropathy is an important cause of functional disability, and current therapies have limited ability to halt its progression. Uridine, a pyrimidine nucleoside essential for the synthesis of membrane phospholipids and neuronal metabolism, appears to be a potential neuroprotective agent, but its impact on motor behavior and peripheral nerve integrity in diabetes remains insufficiently investigated. Our study investigated the effects of chronic uridine supplementation on locomotor performance, neuromuscular electrophysiological manifestations, and morphological changes in the sciatic nerve in a murine model of streptozotocin-induced diabetes. We used male C57BL/6 mice (n = 8/group) that were assigned to three groups: sham (no diabetes), diabetic (streptozotocin-induced, diabetes mellitus, DM+), and diabetic treated with uridine (DM+U). We observed that uridine did not alter the metabolic status, as the HbA1c values remained comparable between diabetic groups (9.93 ± 0.57% DM+ vs. 9.71 ± 0.55% DM+U; p = 0.72), suggesting effects independent of glycemic control. The open field test revealed that diabetic mice showed a marked reduction in spontaneous locomotion, while uridine-treated mice maintained a significantly higher level of activity (longer total distance traveled 3761.7 ± 789.1 cm vs. 2477.5 ± 1017.6 cm in DM+; p = 0.023). Electrophysiological evaluation revealed near-normal sciatic nerve function in DM+U mice, including higher compound motor action potential (CMAP) amplitudes (10.21 ± 0.64 mV vs. 5.75 ± 0.72 mV; p < 0.0001) and reduced F-wave latency (6.35 ± 0.45 ms vs. 7.29 ± 0.31 ms; p < 0.0001). Histological and immunohistochemical analyses (PGP 9.5) further confirmed reduced nerve degeneration in DM+U mice. Our data suggest that chronic uridine administration may confer both functional and structural neuroprotection in diabetic neuropathy, even in the absence of improved glycemic control.Keywords
Funding Information
- University of Medicine and Pharmacy of Craiova, Romania
This publication has 49 references indexed in Scilit:
- Impact of 6-purine modifications on the ribose substrate selectivity of pyrimidine nucleoside phosphorylase (PyNP) in base exchange reactionsCarbohydrate Research, 2025
- State of the art indicators for imaging purinergic dynamics in vitro and in vivoPurinergic Signalling, 2025
- Diabetic neuropathy: cutting-edge research and future directionsSignal Transduction and Targeted Therapy, 2025
- The Role of Inflammation in the Pathogenesis of Diabetic Peripheral Neuropathy: New Lessons from Experimental Studies and Clinical ImplicationsDiabetes Therapy, 2025
- Diabetes mellitus, the fastest growing global public health concern: Early detection should be focusedHealth Science Reports, 2024
- New perspectives in diabetic neuropathyNeuron, 2023
- Piceatannol promotes neuroprotection by inducing mitophagy and mitobiogenesis in the experimental diabetic peripheral neuropathy and hyperglycemia-induced neurotoxicityInternational Immunopharmacology, 2023
- Management of diabetic neuropathyMetabolism, 2021
- Effect of the use of combination uridine triphosphate, cytidine monophosphate, and hydroxycobalamin on the recovery of neurosensory disturbance after bilateral sagittal split osteotomy: a randomized, double-blind trialInternational Journal of Oral and Maxillofacial Surgery, 2016
- Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in ratsBiological Psychiatry, 2005